Pfizer has closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold in the fast-growing obesity market following a fierce bidding war with Novo Nordisk. The greenlight from Metsera’s shareholders paves the way for Pfizer to diversify beyond its shrinking COVID-19 portfolio, navigate looming patent expirations, and tap into the fast-growing weight-loss drug market that analysts estimate could be worth $150 billion annually by the end of the decade. “By acquiring Metsera, we are directing our resources toward one of the most impactful and high-growth therapeutic areas and positioning ourselves to define it,” Pfizer CEO Albert Bourla said in a statement.
Read the full article: Pfizer Completes Up to $10B Acquisition of Metsera //
Source: https://www.msn.com/en-gb/money/other/pfizer-completes-up-to-10-billion-acquisition-of-metsera/ar-AA1QnJcq